

招股概略

锦欣生殖医疗集团有限公司 (1951)

发行数据

集资额: 2,771.28 - 3,049.83 百万港元

发售股份数目: 357.124 百万 **价格:** 7.76 - 8.54 港元

每手股数: 2,000

入场费: 17,252.11 港元 **历史市盈率:** 76.5 倍 – 84.1 倍 **每股有形资产净值:** 1.15 - 1.26 港元

市值(招股后): 18,475-20,332 百万港元

招股开始: 2019年6月13日

招股截止: 2019年6月18日中午12时

上市: 2019年6月25日

保荐人: 摩根士丹利亚洲有限公司及中信里昂证券资本市场有限公司

12月31日止年度	人民币千元	按年变动
收入		
2017年	662,774	91.3%
2018年	921,994	39.1%
年内利润及全面收入总额		
2017年	198,551	91.6%
2018年	212,124	6.8%

背景

- 集团是中美领先的辅助生殖服务(「辅助生殖服务」)供应商。根据弗若斯特沙利文报告,集团中国网络内的辅助生殖医疗机构于 2018 年在中国辅助生殖服务市场中排名第三,进行了 20,958 个体外受精(「IVF」)取卵周期,市场份额约为 3.1%。
- 根据弗若斯特沙利文报告,HRC Fertility(包括由 HRC Management 根据管理服务协议管理的 HRC Medical)于 2018 年在美国西部辅助生殖服务市场中排名第一,进行了 4,500 个 IVF 取卵周期,约占美国西部总市场份额的 7.5%。
- 根据弗若斯特沙利文报告,集团的中国网络内的辅助生殖医疗机构在 2018 年取得了较高的成功率,达 54%,而全国平均水平则为 45%。同样地,根据弗若斯特沙利文报告,于 2016 年,HRC Fertility 的成功率达到 62%,分别高于美国平均水平(53%)及加利福尼亚州的平均水平(57%)。
- 由于生育率上升和最近的政府激励政策(例如 2015 年的二胎政策),中国辅助生殖服务市场从 2014 年到 2018 年以 13.6%的复合年增长率增长,预计 2018 年至 2023 年将以 14.5%的复合年增长率增长。即使辅助生殖服务市场快速增长,2018 年中国的渗透率(计算方法是接受辅助生殖技术服务的夫妇数目除以需要辅助生殖技术服务的不孕夫妇数目)低至 7.0%,且预计 2023 年将增长至 9.2%。

业务策略

- 增加集团的市场份额及提高其生产力和产能;
- 持续投入研发,提升整体表现;
- 继续提升品牌知名度;及
- 通过收购拓展集团的平台。

竞争优势

- 在中国快速发展,且有着巨大需求缺口的市场中占据有利地位的领先辅助生殖服务供应商;
- 美国领先的辅助生殖服务全方位服务供应商;



- 优异的医学业绩奠定骄人的成功率;
- 优化经营模式所带来的高生产率;及
- 资深及具远见卓识的管理团队。

主要风险

- 集团网络内的辅助生殖医疗机构受到严格的行业经营监管。
- 中国医疗行业监管制度的任何不利变动,可能限制集团网络的医疗机构提供辅助生殖服务的能力。
- 如集团网络内的辅助生殖业务未能吸引及留住足够合资格医生、管理人员及其他医护人员数目。
- 集团大部分收益来自及预期来自中国四川省及广东省以及美国加利福尼亚州,或会对有关地区当地状况及转变的不利发展尤为敏感,例如 该等地区的经济、法律及法规以及任何不可抗力事件、天灾或传染病爆发。
- 倘不能取得或维持任何牌照,可能导致集团网络内的辅助生殖医疗机构遭受处罚。
- 倘若管理服务协议的有效性无法维持或管理服务协议根据适用法律终止,则将会严重损害集团的经营业绩及财务状况。
- 集团已就收购确认商誉并可能在日后就收购确认商誉。倘集团厘定集团须将商誉减值,可能会对集团的经营业绩及财务状况造成不利影响。
- 集团拥有商誉以外的无形资产。倘集团的其他无形资产需要减值,则其可能对集团的经营业绩及财务状况造成不利影响。

股息政策

■ 无固定股息政策。

所得款项用途

	(百万港元)	比重
扩建及升级集团位于中国网络的辅助生殖医疗机构及招募医疗专业人员 (包括医生及胚胎学家)	668.6	25.0%
用于潜在收购位于集团目前并无业务的中国省份的额外辅助生殖医疗机 构	534.9	20.0%
用于投资研发	267.4	10.0%
用潜在收购辅助生殖服务服务提供商及沿辅助生殖服务服务链的业务	534.9	20.0%
用于提高在中国及美国的品牌知名度,及整体的辅助生殖服务认知度,如进行学术推广、开发社交媒体工具,及在美国进行营销活动	401.2	15.0%
营运资金及用于一般公司用途	267.4	10.0%
合计	2,674.4	100.0%



Disclosures/Disclaimers

This report is prepared by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is a licensed corporation providing securities brokerage and securities advisory services in Hong Kong.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKHHK. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKHHK may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKHHK and its associates (as defined in the Securities and Futures Ordinance, Chapter 571 of Hong Kong) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKHHK to be reliable. However, UOBKHHK makes no representation as to the accuracy or completeness of such sources or the Information and UOBKHHK accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKHHK and its associates may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKHHK and its associates are subject to change without notice. UOBKHHK reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKHHK, its associates and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKHHK, its associate and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKHHK may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKHHK may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report is prepared by UOBKHHK, a company authorized, as noted above, to engage in securities activities in Hong Kong. UOBKHHK is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKHHK (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKHHK by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKHHK.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.



Analyst Certification/Regulation AC

Each research analyst of UOBKHHK who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKHHK or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKHHK's total revenues, a portion of which are generated from UOBKHHK's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

General	This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to applicable law or regulation.
Hong Kong	This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong Kong and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong Kong in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Indonesia	This report is distributed in Indonesia by PT UOB Kay Hian Securities, which is regulated by Financial Services Authority of Indonesia (OJK). Where the report is distributed in Indonesia and contains research analyses or reports from a foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.
Malaysia	Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the registered person under CMSA to distribute any research analyses in Malaysia.
Singapore	This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Thailand	This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated by the Securities and Exchange Commission of Thailand.
United Kingdom	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.
United States of America ('U.S.')	This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S. laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in the report should contact UOB Kay Hian (US) Inc. directly.

Copyright 2019, UOB Kay Hian (Hong Kong) Ltd. All rights reserved.

http://www.utrade.com.hk